Fractyl Health, Inc.
GUTS Healthcare Biotechnology
Fractyl Health, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $93,000.00, down 22.5% from fiscal 2023. In the quarter to June 2026, revenue fell 57.1%, EPS grew 71.9%, free cash flow grew 25.3% and total debt rose 1.54%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow GUTS
Fractyl Health, Inc. (GUTS) Altman Z-score
Fractyl Health, Inc.'s Altman Z-score for fiscal 2024 is 0.45, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2024 | 0.45 | — |
How fiscal 2024’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.48 | — | 0.58 | |
| Retained earnings / total assets | (3.84) | — | −5.38 | |
| EBIT / total assets | (0.87) | — | −2.86 | |
| Market value of equity / total liabilities | 13.51 | — | 8.11 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Distress zone | 0.45 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −14.81 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| TENX Tenax Therapeutics, Inc. compare | 1.8× |
| GUTS Fractyl Health, Inc. | 0.5× |
| CNTB Connect Biopharma Holdings Limited Sponsored ADR compare | −5.9× |
| RNXT RenovoRx, Inc. compare | −8.0× |
| GOSS Gossamer Bio, Inc. compare | −12.5× |
| BOLD Boundless Bio, Inc. compare | — |
| RNTX Rein Therapeutics Inc. compare | — |
| ELOX Senesco Technologies Inc. compare | — |
| ALPS Alps Group Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets